Table 4.

Results of sensitivity analysis, change in cost accounting perspective

	Base-case scenario (modified societal perspective)			Healthcare-system perspective			Societal perspective
	MBC	EBC	Total	MBC	EBC	Total	MBC	EBC	Total
Direct medical costs (MSEK)
Trastuzumab drug	1411	3787	5198	1411	3787	5198	1411	3787	5198
Trastuzumab administration	33	130	163	33	130	163	33	130	163
Costs of care	1293	215	1508	1293	215	1508	1293	215	1508
Total direct medical costs (MSEK)	2737	4131	6869	2737	4131	6869	2737	4131	6869
Informal care (MSEK)
Trastuzumab-associated	32	118	149				32	118	149
Other	76	37	112				76	37	112
Total cost of informal care (MSEK)	107	155	262				107	155	262
Productivity costs (MSEK)
Trastuzumab-associated	6	25	31				6	25	31
Other	−595	−1645	−2240				−595	−1645	−2240
Total productivity costs (MSEK)	−589	−1620	−2209				−589	−1620	−2209
Total consumption (MSEK)							1116	2244	3360
Total COSTS (MSEK)	2255	2666	4921	2737	4131	6869	3372	4910	8281
Total net monetary value (MSEK)	1819	6696	8515	1337	5231	6568	703	4453	5155
Mean cost/QALY	553,517	284,742	366,241	671,822	441,289	511,192	827,549	524,408	616,328
Net monetary value excluding drug cost (MSEK)	3230	10,483	13,714	2748	9017	11,766	2114	8239	10,353
Share of value to innovator	44%	36%	38%	51%	42%	44%	67%	46%	50%

EBC early breast cancer, MBC metastatic breast cancer, MSEK million Swedish krona, QALY quality-adjusted life year